Neovasc’s Refractory Angina Treatment Receives CE Mark
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
cardiovascular disease
Accord Biosciences Receives $1.3M NIH SBIR Grant To Develop Pulmonary Hypertension Diagnostic
Last year, Accord Biosciences was awarded a Phase II National Institutes of Health Small Business Innovation Research grant of $1.3M to develop a point-of-care diagnostic for pulmonary arterial hypertension.
The Latest Cardiology News
Cameron Health has released positive clinical trial data on a unique therapy to prevent sudden cardiac arrest, a leading cause of death in the U.S.
Resverlogix to Begin Phase II Atherosclerosis Trial
Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease.